Bill Taranto

Theirs was a little bigger where we committed a lot more equity and they committed a lot more equity.

commercial dollars because it's just a bigger market than the Asian markets.

But the same idea was how do we then be able to deploy capital in those markets?

So now we're not only the U.S., we're deploying, I think we have five investments now in the Asia Pacific market.

We have three in the Europe market.

We want to launch this in the Latin American market in the next year to 18 months as we build out those two markets.

So keep expanding, which then gives us a bigger footprint.

And then over time, I think the goal is

would be if these grow to a certain size, we would like to have personnel sitting in those markets.

Expand GHI to have a local staff in the Asian market, local staff in Europe, and a local staff in Latin America.

And then that would truly make us a global investing arm.

But we're doing the best we can with the resources we have and the way we're structured as a kind of a U.S.-focused arm.

But the reality is we have to pay attention globally.

And it's allowed us to do that without, you know,

doing too much infrastructure costs of putting people in place yet, but allowing us to use the infrastructure of Merck with our MSD organizations to build these out.

But this has been really successful the last 18 months.

And gentlemen and myself, Joel Crixton has been leading that.

And it's been one of our very successful venture ideas that we've had in the last 18 months.

Yeah, well, certainly AI is going to dominate the conversation, right?

And that's going to be the driver of a lot of investment in health care.